- Home
- ICCM vs RFL Comparison
ICCM vs RFL Comparison
Compare ICCM & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ICCM | RFL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 61.1M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ICCM | RFL |
|---|---|---|
| Price | $0.68 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 175.5K | 92.9K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.54 | $1.12 |
| 52 Week High | $1.53 | $3.19 |
Technical Indicators
Market Signals| Indicator | ICCM | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 48.08 |
| Support Level | $0.68 | $1.15 |
| Resistance Level | $0.74 | $1.38 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 79.21 | 30.00 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.